**Core Concept**
Butorphanol is a synthetic opioid agonist-antagonist that has been formulated for intranasal administration, allowing for rapid absorption and onset of action. This unique formulation is used for the treatment of moderate to severe pain, particularly for acute migraine headaches.

**Why the Correct Answer is Right**
Butorphanol's intranasal formulation exploits the rich blood supply of the nasal mucosa, which facilitates rapid absorption of the medication into the systemic circulation. This leads to a relatively quick onset of analgesia, typically within 30 minutes. The intranasal route also avoids the first-pass metabolism, resulting in higher bioavailability compared to oral or parenteral administration.

**Why Each Wrong Option is Incorrect**
**Option A:** Tramadol is an opioid analgesic with a different pharmacological profile, primarily acting as a serotonin-norepinephrine reuptake inhibitor. It is not formulated for intranasal administration.
**Option B:** Pethidine (meperidine) is a weak opioid agonist, but it is not suitable for intranasal use due to its potential for abuse and limited efficacy in pain management.
**Option D:** Buprenorphine is a partial opioid agonist used for the treatment of opioid use disorder and pain management, but it is typically administered sublingually or transdermally, not intranasally.

**Clinical Pearl / High-Yield Fact**
When choosing opioid analgesics, consider the specific pharmacological profile, route of administration, and potential for abuse or dependence. Butorphanol's unique intranasal formulation makes it an attractive option for acute pain management, particularly in settings where rapid onset of action is crucial.

✓ Correct Answer: C. Butorphanol